Acute Lymphoblastic Leukemia

• Disruption of normal B-cell or T-cell development: Leukemic blasts are arrested at early stages of lymphoid maturation (pro-B, pre-B, or early T-cell stages). Normal lymphoid development requires precise regulation of V(D)J recombination and transcription factor expression; malignant transformation occurs when recombination-activating gene (RAG)-mediated DNA recombination goes awry or when ectopic expression of oncogenic transcription factors (e.g., MYC, HOX11, TAL1) occurs. This results in accumulation of phenotypically immature, functionally incompetent cells that escape negative selection and differentiation checkpoints. The arrested blasts retain proliferative capacity while losing ability to undergo normal apoptosis or terminal differentiation.

• Chromosomal translocations and fusion genes: Most ALL cases harbor recurrent chromosomal abnormalities that create fusion genes with oncogenic potential. The t(9;22) Philadelphia chromosome (present in 20-25% of adult ALL, 3-5% of pediatric ALL) produces the BCR-ABL1 fusion gene, encoding a constitutively active tyrosine kinase that hyperactivates RAS/MAPK and PI3K/AKT pathways, driving proliferation and blocking apoptosis. The t(12;21) ETV6-RUNX1 (present in 20-25% of pediatric B-ALL) disrupts transcriptional regulation of early lymphoid development. t(1;19) TCF3-PBX1 impairs B-cell differentiation. t(4;11) KMT2A-AFF1 (and other KMT2A rearrangements) involving the histone methyltransferase KMT2A gene produce aggressive leukemias with immature morphology, particularly in infants and older adults. t(8;14) MYC translocations (hallmark of Burkitt leukemia/lymphoma) place the MYC oncogene under control of immunoglobulin heavy chain (IGH) enhancer, resulting in MYC overexpression and constitutive proliferation. These fusion proteins typically act as dominant oncogenic drivers.

• Loss of tumor suppressors and impaired cell cycle control: ALL frequently exhibits deletion or mutation of TP53, RB1, CDKN2A/CDKN2B, and IKZF1 genes. Loss of these checkpoint proteins allows cells to bypass G1/S and G2/M checkpoints, progress through the cell cycle unchecked, and survive DNA damage that normally triggers apoptosis. IKZF1 deletions are particularly common in B-ALL (especially in older adults and Ph+ disease) and associated with poor prognosis; IKZF1 encodes Ikaros, a transcription factor essential for lymphoid development and tumor suppression. TP53 mutations prevent p53-mediated apoptosis in response to DNA damage, proliferative signals, or hypoxia.

• Activation of PI3K/AKT/mTOR and RAS/MAPK pathways: Both pathways are dysregulated in most ALL cases through various mechanisms: activating mutations in PIK3CA or PTEN loss activate PI3K/AKT; NRAS/KRAS mutations (present in 20-30% of ALL) activate MAPK cascades; BCR-ABL1 and other kinase fusions directly phosphorylate and activate these pathways. These signaling cascades promote anabolic metabolism, protein translation, and survival while suppressing apoptotic and differentiation signals. Activation of mTOR enhances ribosomal biogenesis and protein synthesis supporting rapid proliferation.

• Impaired apoptosis through BCL-2 overexpression and loss of pro-apoptotic signals: BCL2 is frequently overexpressed through various mechanisms (translocations, increased expression from IGH locus control regions in B-ALL, epigenetic changes). BCL-2 proteins sequester pro-apoptotic BAX/BAK proteins, preventing mitochondrial outer membrane permeabilization and cytochrome c release. Simultaneously, loss of pro-apoptotic BIM or impaired death receptor signaling (via FAS/FASL mutations) further tip the balance toward survival. Blasts become resistant to chemotherapy-induced apoptosis, contributing to drug resistance.

• Altered metabolism favoring leukemic proliferation: ALL blasts upregulate glucose uptake and glycolysis (Warburg effect) via MYC-driven and PI3K/AKT-driven metabolic reprogramming. This shift supports rapid ATP generation and biosynthetic precursor synthesis despite lower efficiency. Enhanced glutaminolysis and lipogenesis support nucleotide synthesis and cell membrane biogenesis. Altered mitochondrial metabolism with increased oxidative phosphorylation in some ALL subtypes and glycolytic dominance in others provides metabolic flexibility to escape therapy targeting single pathways.

• Immune escape mechanisms: Leukemic blasts downregulate human leukocyte antigen (HLA) expression and adhesion molecules, reducing recognition by immune surveillance. They may express ligands for inhibitory immune checkpoints (PD-L1, PD-L2) that engage T-cell PD-1, suppressing anti-leukemic immunity. Some blasts produce immunosuppressive cytokines (IL-10, TGF-β). These mechanisms allow leukemic expansion despite presence of functionally intact immune system, underlying rationale for immune-based therapies (CAR-T cells).

• Prior exposure to ionizing radiation: Therapeutic radiation to chest, head, or pelvis (for prior malignancies, leukemia prophylaxis, or spinal therapy) increases ALL risk 5-10 fold, with latency period of 2-20 years. Atomic bomb radiation exposure in Japanese survivors of WWII showed clear dose-response relationship for leukemia development. High-dose radiation used in conditioning regimens for hematopoietic stem cell transplantation (HSCT) carries increased secondary leukemia risk.

• Chemotherapy exposure: Prior treatment with topoisomerase II inhibitors (etoposide, doxorubicin) for other malignancies increases secondary ALL risk, typically with short latency (2-5 years). Alkylating agents (cyclophosphamide, busulfan) also increase risk with longer latency (5-10 years). Secondary leukemias (therapy-related ALL) often harbor complex karyotypes or KMT2A rearrangements and carry worse prognosis than de novo ALL.

• Genetic predisposition and inherited syndromes: Down syndrome (trisomy 21) confers 10-20 fold increased ALL risk, particularly B-ALL with ETV6-RUNX1 fusion; this increased risk likely relates to extra copies of genes on chromosome 21 (including genes involved in cell cycle, apoptosis, and metabolism). Ataxia-telangiectasia (ATM mutations) increases lymphoid malignancy risk through impaired DNA repair and checkpoint control. Li-Fraumeni syndrome (TP53 mutations) confers modestly increased leukemia risk among other malignancies. Fanconi anemia, Bloom syndrome, and Nijmegen breakage syndrome (all DNA repair deficiencies) increase leukemia risk. IKZF1 polymorphisms identified in genome-wide association studies (GWAS) contribute to ALL susceptibility in the general population. Familial clustering of ALL is rare but has been reported.

• Immunosuppression: Patients with congenital immunodeficiency (especially severe combined immunodeficiency—SCID), HIV/AIDS (though less common in era of highly active antiretroviral therapy), and chronic immunosuppression post-transplant have mildly increased ALL risk, though leukemia remains rare.

• Inflammatory conditions and chronic antigen stimulation: Chronic antigenic stimulation (viral infections, autoimmune diseases) may increase T-cell ALL risk; however, definitive causal relationships remain unestablished.

• Environmental exposures: Maternal exposure to diethylstilbestrol (DES) during pregnancy has been weakly associated with increased offspring leukemia risk. Parental occupational exposures to benzene, pesticides, or electromagnetic fields show inconsistent associations. No convincing evidence links household exposures (electromagnetic fields, power lines) to ALL.

• Prior hematologic disorders: Chronic myeloid leukemia (CML) can undergo blast crisis transformation to ALL (25-30% of CML patients at blast crisis). Myelodysplastic syndrome (MDS) rarely progresses to ALL.

• Fatigue, weakness, and dyspnea on exertion: Resulting from severe anemia (median hemoglobin 7-10 g/dL at presentation) caused by displacement of erythroid progenitors by leukemic blasts. Blasts occupy >80% of marrow cellularity, obliterating normal hematopoiesis. Reduced oxygen-carrying capacity manifests as dyspnea on exertion, tachycardia, and fatigue that may be mistaken initially for viral illness.

• Fever, chills, and infection: Resulting from severe leukopenia (absolute neutrophil count often <500/μL or paradoxically very high with leukostasis risk). Despite markedly elevated white blood cell counts in some patients (reaching 500,000/μL or higher), the blasts are non-functional and provide no antimicrobial defense. Leukemic blasts may directly impair neutrophil function through competition for nutrients or production of immunosuppressive factors. Patients present with community-acquired pneumonia, bacteremia, fungal infections (Pneumocystis jirovecii, Candida, Aspergillus), or opportunistic infections. Fever may be absence of documented infection (leukemic fever from cytokine release).

• Petechiae, ecchymoses, and bleeding manifestations: Resulting from severe thrombocytopenia (platelets <50,000/μL in 50% of patients, <10,000/μL in 25%). Bleeding may be spontaneous or triggered by minor trauma. Disseminated intravascular coagulation (DIC) (particularly with promyelocytic-like ALL or high-blast burden) contributes through consumption of clotting factors and fibrinogen, causing both microvascular thrombosis and bleeding. Patients may present with epistaxis, gingival bleeding, mucosal hemorrhages, hematuria, melena, or hemorrhagic stroke. Life-threatening hemorrhage into the CNS or GI tract can occur.

• Bone pain and arthralgias: Occurring in 25-50% of patients, particularly children, from rapid expansion of blast infiltrate within bone marrow cavity, stretching periosteum, and triggering bone pain nerve endings. Pain is typically pleuritic, worse with movement or pressure, and may be misattributed to rheumatologic disease.

• Lymphadenopathy and splenomegaly: Occurring in 50% and 25-50% of patients, respectively, from infiltration by leukemic blasts into lymphoid tissues. Patients may present with neck or axillary masses noticed incidentally. Massive splenomegaly (spleen >5 cm below costal margin) occurs in ~10% and may cause early satiety, abdominal distention, or splenic rupture if traumatized. Hepatomegaly occurs in 40% from extramedullary leukemic infiltration.

• Mediastinal mass and respiratory compromise: Occurring in 20-25% of T-ALL cases and 10% of B-ALL cases (particularly those with high blast burden). Large anterior mediastinal masses may compress airways, causing stridor, cough, dyspnea, or superior vena cava (SVC) syndrome with facial plethora, neck vein distention, and upper extremity edema. Mediastinal masses can impair cardiac function through pericardial effusion or direct compression. Patients at risk for acute airway obstruction, particularly with general anesthesia or sedation.

• CNS involvement (leukostasis and leukemic meningitis): Present at diagnosis in 5-10% of CNS-positive disease. CNS leukostasis occurs with extremely high white blood cell counts (>200,000/μL, particularly T-ALL), causing mechanical plugging of cerebral microvasculature with subsequent hypoxia and hemorrhage. Patients present with altered mental status, visual disturbances, seizures, headache, or coma. Leukemic meningitis (arachnoid infiltration by blasts) causes headache, neck stiffness, photophobia, and cranial nerve palsies if untreated. Cerebrospinal fluid (CSF) shows elevated opening pressure, elevated protein (>100 mg/dL), low glucose, and positive blast count.

• Testicular involvement: Occurs in 5-10% of male patients, presenting as unilateral or bilateral testicular enlargement; testicular ALL may persist despite complete hematologic remission and can serve as sanctuary site for relapse.

• Physical examination findings:
• Petechiae and ecchymoses on skin and mucous membranes from thrombocytopenia
• Pallor from severe anemia
• Hepatosplenomegaly from leukemic infiltration (present in 50-70%)
• Lymphadenopathy (cervical, axillary, inguinal) in 50%
• Gingival infiltration and gingival bleeding particularly in monocytic lineage (more common in AML but can occur in ALL)
• Fundoscopic examination may show retinal hemorrhages ("Roth spots"), cotton-wool spots, or leukostatic retinopathy with blurred vision

• Atypical presentations:
• Presentation as isolated CNS disease with meningismus before hematologic involvement detected
• Mediastinal mass as sole presenting finding in T-ALL, discovered on routine chest X-ray for dyspnea
• Presentation with lymphoma-like picture (mediastinal mass, lymphadenopathy) without significant peripheral blood involvement
• Older adults (>60 years) may present more insidiously with milder cytopenias and higher burden of comorbidities complicating treatment tolerance

• Peripheral blood smear and complete blood count: Initial screening demonstrates profound leukocytosis (WBC >100,000/μL in 50% of cases) or leukopenia (WBC <10,000/μL in 30%), with numerous circulating blasts visible on Wright-Giemsa staining. Blasts appear as large cells with scant cytoplasm, fine nuclear chromatin, and prominent nucleoli. Auer rods (abnormal azurophilic granular inclusions in cytoplasm) are absent in ALL but present in AML, useful for differentiation. Concurrent severe anemia (hemoglobin typically 7-10 g/dL) and thrombocytopenia (platelets <100,000/μL in 75% of cases, <10,000/μL in 25%) are typical. Red blood cell morphology may show nucleated RBCs from severe marrow stress. Absolute neutrophil count is often paradoxically low despite high WBC (due to overwhelming blast predominance), contributing to infection risk.

• Bone marrow aspiration and biopsy with morphology: Gold standard for diagnosis. Aspirate demonstrates replacement of normal marrow architecture by >80% blasts (diagnostic threshold is

Immediate stabilisation (before cytoreduction)

• Tumor lysis prophylaxis: aggressive IV isotonic fluids plus a xanthine oxidase inhibitor (allopurinol) for standard risk, or recombinant urate oxidase (rasburicase) for high blast burden/renal impairment, as recommended by NCCN. Rasburicase converts uric acid to soluble allantoin and is contraindicated in G6PD deficiency (hemolysis, methemoglobinemia). Avoid routine urinary alkalinization and avoid loading calcium for asymptomatic hypocalcemia (promotes calcium-phosphate deposition).
• Febrile neutropenia: blood cultures then immediate empiric anti-pseudomonal beta-lactam (cefepime or piperacillin-tazobactam) per IDSA — do not wait for a source.
• Transfusion and coagulopathy support: cellular products should be irradiated (prevents transfusion-associated GVHD) and leukoreduced (reduces CMV transmission, febrile non-hemolytic reactions, and HLA alloimmunization); correct DIC with cryoprecipitate/FFP.
• Leukostasis or bulky anterior mediastinal mass: hydration and prompt cytoreduction; anticipate airway collapse with sedation/general anesthesia in T-ALL mediastinal masses.

• Induction backbone: a corticosteroid (prednisone or dexamethasone) + vinca alkaloid (vincristine) + asparaginase (pegaspargase) ± an anthracycline (daunorubicin).
• CNS-directed therapy in every patient: intrathecal methotrexate/cytarabine ± high-dose systemic methotrexate, because the CNS and testes are pharmacologic sanctuary sites. Vincristine is never given intrathecally — it is uniformly fatal.
• Maintenance: daily 6-mercaptopurine + weekly methotrexate with pulses of vincristine/steroid. Reduce 6-MP if allopurinol is co-administered (xanthine oxidase blockade raises 6-MP levels); check TPMT/NUDT15 status.
• Ph-positive (BCR-ABL1) ALL: add a tyrosine kinase inhibitor (imatinib or dasatinib) to chemotherapy or to steroids alone in frail patients — NCCN recommends TKI-based therapy for all Ph+ disease.
• Adolescents and young adults do better with pediatric-inspired asparaginase-intensive regimens than adult regimens.

Escalation and definitive therapy

• Relapsed/refractory or MRD-positive B-ALL: blinatumomab (CD19×CD3 bispecific T-cell engager), inotuzumab ozogamicin (anti-CD22 antibody–drug conjugate), or CD19 CAR-T cells (tisagenlecleucel).
• Allogeneic hematopoietic stem cell transplant in first remission for high-risk cytogenetics or persistent measurable residual disease; MRD by flow/PCR drives these decisions.
• Contraindicated: live vaccines during therapy, IM injections/aspirin/NSAIDs in severe thrombocytopenia, and empiric corticosteroids before a diagnostic marrow (they lyse blasts and obscure diagnosis).

Disease- and cytoreduction-related emergencies

• Tumor lysis syndrome (EMERGENCY): massive blast lysis releases intracellular contents — hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia with acute kidney injury from urate and calcium-phosphate crystal deposition. Signalled by rising creatinine and potassium within 12–72 hours of starting therapy; peaked T waves or tetany mandate immediate action, including renal replacement therapy if refractory.
• Febrile neutropenia / sepsis (EMERGENCY): absent functional neutrophils plus mucosal barrier injury; a single fever in a neutropenic patient is the signal and requires antibiotics within an hour (IDSA).
• Leukostasis (EMERGENCY): hyperleukocytosis plugs cerebral and pulmonary microvasculature — hypoxia, confusion, retinal hemorrhage; less common in ALL than AML because lymphoblasts are less adherent.
• DIC and intracranial hemorrhage (EMERGENCY): tissue-factor release with consumptive coagulopathy; low fibrinogen, high D-dimer, schistocytes.

Treatment toxicities by agent

• Asparaginase: depletes asparagine and all hepatic proteins including antithrombin and fibrinogen — cerebral sinus venous thrombosis, pancreatitis, and hyperglycemia; new headache/seizure on therapy demands MR venography.
• Anthracyclines: free-radical, topoisomerase-IIβ–mediated cardiomyocyte injury — dose-dependent cardiomyopathy; falling LVEF on surveillance echo.
• Vincristine: microtubule disruption causing length-dependent peripheral neuropathy, foot drop, and ileus/constipation. Intrathecal administration is a fatal never-event.
• Methotrexate: mucositis, myelosuppression, nephrotoxicity, and leukoencephalopathy; rescue with leucovorin and monitor levels.
• Corticosteroids: avascular necrosis of the femoral head (classically in adolescents), hyperglycemia, myopathy, and Pneumocystis jirovecii pneumonia — hence TMP-SMX prophylaxis.
• Blinatumomab and CAR-T: T-cell activation produces two distinct syndromes that are graded and treated separately (ASTCT consensus grading, NCCN):
• Cytokine release syndrome: fever, hypotension, hypoxia with high ferritin/CRP — supportive care plus tocilizumab (IL-6 receptor blockade), adding corticosteroids for higher grades.
• ICANS / neurotoxicity (EMERGENCY): encephalopathy, aphasia, tremor, seizure — treat with corticosteroids (dexamethasone) and interruption of the offending drug. Tocilizumab does not treat isolated neurotoxicity (IL-6 blockade does not penetrate the CNS and may raise CNS IL-6) and is added only for concurrent CRS. Blinatumomab neurotoxicity is likewise managed by infusion interruption plus steroids.
• Inotuzumab ozogamicin: sinusoidal obstruction syndrome (veno-occlusive disease) — tender hepatomegaly, weight gain, jaundice, especially before/after transplant.

Late complications

• Sanctuary-site relapse: CNS (cranial neuropathy, blasts in CSF) and testicular (painless testicular enlargement).
• Therapy-related myeloid neoplasm: topoisomerase II inhibitors cause KMT2A-rearranged secondary AML with short latency.
• Chronic GVHD, endocrinopathy, and infertility after allogeneic transplant and total body irradiation.

• TdT is the classic marker of immaturity, not a stand-alone diagnostic test: terminal deoxynucleotidyl transferase marks immature B- and T-lymphoblasts, but it is not lineage-specific (expressed in a minority of AML cases) and is characteristically negative in mature B-cell/Burkitt leukemia. Definitive diagnosis rests on the full flow cytometry immunophenotype — CD19/CD10/cytoplasmic CD79a/cCD22 for B-lineage, cytoplasmic CD3/CD7 for T-lineage, and MPO for myeloid.
• Single best next step for suspected acute leukemia: peripheral smear plus bone marrow aspiration/biopsy with flow cytometry, cytogenetics, and FISH — never start empiric corticosteroids first, since they lyse blasts and can render the marrow non-diagnostic.
• The association examiners test most: t(9;22) BCR-ABL1 (Philadelphia chromosome) — poor prognosis, more common in adults, and the answer to "what changes management?" is add a tyrosine kinase inhibitor (imatinib/dasatinib) to chemotherapy (NCCN).
• Prognostic pairs: t(12;21) ETV6-RUNX1 and hyperdiploidy = favorable, pediatric; KMT2A (11q23) rearrangement in infants, hypodiploidy, and Ph+ = unfavorable. CD10 (CALLA) marks common B-ALL.
• Teenage boy with a mediastinal mass, SVC syndrome, and cytopenias = T-ALL (thymic origin). Distinguish from Hodgkin lymphoma by the presence of circulating blasts and marrow involvement.
• Every patient gets CNS prophylaxis with intrathecal chemotherapy, even without CSF blasts, because the CNS and testes are sanctuary sites; a painless enlarged testis after remission is relapse, not orchitis.
• Before the first dose of chemotherapy, give TLS prophylaxis: IV fluids plus allopurinol, or rasburicase if the blast burden or LDH is high — but check G6PD status first (hemolysis risk).
• Common distractors to avoid: Auer rods, MPO, and gum hypertrophy point to AML, not ALL; PAS block positivity supports B-ALL but is not required; Down syndrome predisposes to both transient abnormal myelopoiesis and ALL, and children with ALL and Down syndrome need methotrexate dose care; persistent bone pain with cytopenias in a child is leukemia until a CBC and smear say otherwise — not growing pains or juvenile idiopathic arthritis.